8-K: MetaVia Presents Promising Phase 1 Data for DA-1726

MetaVia Inc. announced new Phase 1 data for its dual agonist DA-1726 at EASL 2026, showing significant weight reduction and early liver improvements.

Summary

• MetaVia Inc. presented new Phase 1 data for its investigational drug DA-1726 at the European Association for the Study of the Liver Congress 2026.
• DA-1726 is a novel dual oxyntomodulin (OXM) analog targeting GLP-1 and glucagon receptors.
• The 48 mg dose cohort in obese adults showed a mean body weight reduction of up to 9.1% by Day 54 without a plateau.
• Waist circumference also decreased by up to 9.8 cm by Day 54.
• Exploratory FibroScan assessments indicated early, non-invasive liver-related improvements.
• The drug was generally well-tolerated with mild-to-moderate gastrointestinal side effects, and no serious adverse events or treatment discontinuations were observed.
• No clinically meaningful changes in cardiovascular parameters were noted.
• Ongoing Phase 1 studies are evaluating longer-term dosing and higher exposures.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, with promising early-stage data for DA-1726 demonstrating significant weight loss and encouraging liver-related signals, supporting continued investment in its development.

Positives

• Achieved up to 9.1% mean body weight reduction at the 48 mg dose by Day 54, without evidence of a plateau.
• Demonstrated a reduction in waist circumference of up to 9.8 cm by Day 54.
• Exploratory FibroScan findings showed early and consistent improvements in liver biomarkers.
• DA-1726 was generally well-tolerated up to the 48 mg dose.
• No serious adverse events or treatment-related discontinuations were observed.
• Gastrointestinal adverse events were primarily mild-to-moderate and transient.
• No clinically meaningful changes in cardiovascular parameters (heart rate, QTcF) were observed.
• The drug has potential for treating obesity and metabolic dysfunction-associated steatohepatitis (MASH).

Negatives

• Gastrointestinal adverse events, though mild-to-moderate and transient, were present.
• The data presented is from Phase 1 studies, requiring further validation in larger trials.

Risks

• The company has a history of net losses and may need to raise additional capital.
• Adverse global economic conditions could impact the company.
• Regulatory approval timelines and success are uncertain.
• Clinical trial results may not be consistent with pre-clinical or previous trial results.
• Potential negative interactions between product candidates and other treatments.
• Risks associated with the license agreement with Dong-A ST Co. Ltd., including litigation.
• Reliance on contract manufacturers and clinical study partners.
• Uncertainty regarding the stock price and changes in applicable laws and regulations.

Future Outlook

The company is advancing ongoing Phase 1 Part 3a/3b titration studies to evaluate longer-term dosing strategies, optimize tolerability at higher exposures, and further assess the durability of metabolic and liver-related effects of DA-1726.

Management Comments

• "These late-breaking Phase 1 findings presented at EASL 2026 continue to reinforce DA-1726s differentiated metabolic profile as a dual GLP-1 and glucagon receptor agonist with meaningful effects on both body weight, waist circumference and liver-related parameters."
• "Importantly, DA-1726 demonstrated robust and progressive weight loss up to 9.1% at the 48 mg dose level without evidence of plateau, while maintaining favorable tolerability even in the absence of dose titration."
• "We are also encouraged by the exploratory FibroScan findings, which demonstrated early and consistent improvements across multiple noninvasive liver biomarkers, including liver stiffness, CAP and FAST scores."
• "These findings further illustrate the potential of DA-1726 in obesity and MASH, where metabolic and hepatic dysfunction are closely linked."
• "Based on these findings, we continue to advance the ongoing Phase 1 Part 3a/3b titration studies designed to evaluate longer-term dosing strategies, optimize tolerability at higher exposures, and further assess durability of metabolic and liver-related effects."

Industry Context

StockSavvy.ai notes that the presentation of these Phase 1 data for DA-1726 positions MetaVia Inc. within the highly competitive and rapidly evolving market for obesity and metabolic disease treatments, particularly those targeting GLP-1 and glucagon receptors. The dual-agonist approach aims to offer differentiated efficacy compared to existing GLP-1 receptor agonists.

Comparison to Industry Standards

• In pre-clinical mouse models, DA-1726 showed improved weight loss compared to semaglutide (Wegovy).
• In pre-clinical mouse models, DA-1726 elicited similar weight reduction to tirzepatide (Zepbound) and survodutide, while consuming more food, preserving lean body mass, and demonstrating improved lipid-lowering effects compared to survodutide.
• The 48 mg dose in Phase 1 showed up to 9.1% body weight reduction, which is competitive with other agents in development for obesity, though direct comparisons are limited due to different study designs and phases.

Stakeholder Impact

• Shareholders: Positive impact due to promising clinical data that could increase the value of the company's lead asset.
• Patients: Potential future benefit from a new treatment option for obesity and MASH.
• Healthcare Providers: May see a new therapeutic option to consider for patients with cardiometabolic diseases.

Next Steps

• Continue advancing ongoing Phase 1 Part 3a/3b titration studies.
• Evaluate longer-term dosing strategies for DA-1726.
• Optimize tolerability at higher exposures of DA-1726.
• Further assess the durability of metabolic and liver-related effects of DA-1726.

Key Dates

Recommendation

The Phase 1 data is promising, but it is still very early-stage. While the results are positive and support continued development, further clinical trials (Phase 2 and 3) are necessary to confirm efficacy, safety, and long-term outcomes before a stronger recommendation can be made. The company also faces ongoing risks related to its financial position and the competitive landscape.

Keywords

DA-1726, Obesity, MASH, GLP1R agonist, GCGR agonist, Oxyntomodulin, Phase 1 Data, Biotechnology